PG-102(ProGen) Drug Asset Due Diligence Report 2026

This PG-102(ProGen) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether PG-102(ProGen) can convert its Fc fusion protein profile and GLP-1R x GLP-2R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	PG-102(ProGen) (query alias: PG-102(ProGen))
Modality / target	Fc fusion protein; GLP-1R x GLP-2R; GLP-1R agonists, GLP-2R agonists
Highest global status	Phase 2
Originator	ProGen Co., Ltd.
Active developers	ProGen Co., Ltd., Rani Therapeutics Holdings, Inc., Rani Therapeutics LLC

The MCP disease footprint includes Diabetes Mellitus, Type 2, Obesity, Type 2 diabetes mellitus in obese. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
KCT0012302	Phase 2	Not yet recruiting	30	Primary endpoint not disclosed in English source
NCT07677891	Phase 2	Not yet recruiting	60	Primary endpoint not disclosed in English source
NCT07187856	Phase 2	Not yet recruiting	80	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

PG-102, a Novel Bispecific GLP-1R/GLP-2R Fc-Fused Agonist—Data on Safety, Tolerability, and Pharmacokinetics (PK) in Single Ascending Dose Trial in Healthy Subjects and Preliminary Population PK Modeling

Phase 1; n=40; evaluation: Positive. Reported fields: TEAE = Treatment-emergent adverse events (TEAEs) were primarily gastrointestinal, including dyspepsia, nausea, and vomiting, consistent with the GLP-1RA drug class. ; TEAE = Treatment-emergent adverse events (TEAEs) were primarily gastrointestinal, including dyspepsia, nausea, and vomiting, consistent with the GLP-1RA drug class.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

PG-102(ProGen) addresses Diabetes Mellitus, Type 2, Obesity, Type 2 diabetes mellitus in obese. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fc fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-06-24	Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO